Differences between neratinib and neratinib and clinical selection recommendations

Neratinib (Neratinib), also transliterated as neratinib, is actually a different Chinese translation of the same drug. Its common English name is "Neratinib". Due to certain differences in the translation of drug names at home and abroad, patients may be confused when looking up information. In order to help patients understand more clearly the clinical application, mechanism and usage recommendations of neratinib, this article will provide a detailed analysis of this targeted drug and provide clinical selection suggestions.

1. Neratinib (neratinib) only has a different name but is essentially the same

First of all, let’s be clear: neratinib and neratinib are exactly the same drugs. The two are just different expressions in translation and do not mean there are differences in efficacy, ingredients or indications. Its English name "Neratinib" is a general name. In different domestic medical literature, pharmaceutical company information, and drug approval processes, it is sometimes translated as "neratinib" and sometimes called "neratinib". The clinical uses of the two are exactly the same, and patients do not need to be confused by the different names.

Neratinib (Neratinib) is an oral small molecule irreversible panHER tyrosine kinase inhibitor that can simultaneously inhibitHER1 (EGFR), HER2 and HER4 pathways. It plays a key role in the treatment of HER2 positive breast cancer, especially in the continuation treatment phase after patients complete adjuvant treatment with trastuzumab (Herceptin), which can further reduce the risk of breast cancer recurrence.

2. Indications and clinical status of neratinib

Currently, neratinib is widely used as adjuvant continuation treatment for HER2 positive early breast cancer patients, especially those who start taking trastuzumab within one year after completing treatment. In this population, neratinib can significantly prolong disease-free survival and reduce the probability of disease recurrence.

In addition, some studies are exploring its use in combination with capecitabine to treat advanced or metastatic HER2-positive breast cancer. Because it has the characteristics of irreversible pan-HER inhibition, it may also have a certain effect on HER2 mutant subtypes. Therefore, exploratory research has also been carried out in HER2 mutant solid tumors (such as biliary tract cancer and lung cancer).

3. Precautions and adverse reactions during clinical use

In clinical practice, the main adverse reaction of neratinib is diarrhea, which is especially obvious in the early stages of treatment. About more than 90% of patients will experience varying degrees of diarrhea, and some may even affect daily life. Therefore, doctors often combine antidiarrheal drugs such as loperamide in the early stages of medication to improve patient tolerance and compliance.

In addition to diarrhea, patients may also experience side effects such as nausea, vomiting, fatigue, rash, and abnormal liver function. Therefore, it is necessary to monitor liver function and assess gastrointestinal tolerance during use.

It is recommended that patients take neratinib strictly according to the dosage under the guidance of a doctor, and establish a reasonable side effect management mechanism before, during and after treatment, so as to maximize treatment benefits.

4. Clinical Selection Suggestions and User Groups

1.Applicable people: Neratinib is mainly suitable for patients with HER2 positive early breast cancer, especially those with a high risk of recurrence after completing trastuzumab treatment, such as those with large tumors and lymph node metastasis. For patients who have been treated with Herceptin but still have concerns about recurrence, neratinib has obvious value as a continuation treatment.

2. Not recommended for people: People with severe liver function impairment, pregnant or lactating women should use this drug with caution or should not use it. At the same time, for those who cannot tolerate oral treatment or have severe gastrointestinal reactions, the risks of medication also need to be assessed.

3.How to choose: For HER2 positive breast cancer patients, if they have completed trastuzumab treatment, they can evaluate whether additional neratinib treatment is needed based on the disease risk. If patients are worried about drug side effects, especially diarrhea, they need to prepare for intervention in advance, such as using antidiarrheal drugs, and follow the doctor's recommendations for dosage adjustments.

4. Drug channels: Neratinib is currently on the market in many countries and regions and has been included in some medical insurance systems. In mainland China, the drug has not yet been fully included in the national medical insurance catalog, but it can be purchased through specialty drug channels in some areas. There are also generic versions sold in India and other countries, and the price is more advantageous than the original drug.

Neratinib (neratinib) is essentially a different translated name for the same drug, and patients do not need to be troubled by the name difference. In patients with HER2 positive breast cancer, this drug, as a continuation method after adjuvant treatment with trastuzumab, can effectively reduce the risk of recurrence and improve disease-free survival. Although there are certain side effects, especially diarrhea, they can be controlled through preventive medication under the guidance of a doctor. In the future, if the drug can be further promoted and included in medical insurance, it is expected to bring substantial therapeutic benefits to more patients. Neratinib is an important option to consider for HER2-positive patients who are currently looking for continuation treatment options.

Reference materials:https://www.drugs.com/